P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Sundov, Dinka ^a   Caric, Ana ^a   Mrklic, Ivana ^a   Gugic, Dijana ^a   Capkun, Vesna ^a   Hofman, Irena Drmic ^a   Mise, Branka Petric ^a   Tomic, Snjezana ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Carcinogenesis; Karzinogenesis; Ovar; Ovary; ser se Karzinome; Serous Carcinomas; Typ I Tumoren; Typ II Tumoren; Type I; Type II

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; KI 67 ANTIGEN; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN P53; RAS PROTEIN; TP53 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOMA; CHEMISTRY; CHI SQUARE DISTRIBUTION; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MICRODISSECTION; MIDDLE AGED; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICRODISSECTION; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

MLCS; MLOWN;

EID: 84873269293     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-21     Document Type: Article

References (38)

1. Seidman JD, Cho KR, Ronnett BM, Kurman RJ. Surface Epithelial Tumors of the Ovary, (Chapter 14). Blaustein's Pathology of the Female Genital Tract 2011, 680-772. New York: Springer, Kurman RJ, Ellenson LH, Ronnett BM, 6th.
2. Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karseladze AI, Hauptmann S, Rutgers J, Russell P, Buckley CH, Pisani P, Schwartz P, Goldgar DE, Silva E, Caduff R, Kubik-Huch RA. Tumours of the Ovary and Peritoneum, (Chapter 2). The World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003, 113-197. Lyon: IARC Press, Tavassoli FA, Devilee P.
3. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer. Lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008, 27(2):151-160. 2794425, 18317228.
4. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009, 16(5):267-282. 10.1097/PAP.0b013e3181b4fffa, 2745605, 19700937.
5. Seidman JD, Horkayne-Szakaly I, Cosin JA, Riu HS, Haiba M, Boice CR, Yemelyanova AV. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol 2006, 103(2):703-708. 10.1016/j.ygyno.2006.05.030, 16828848.
6. Fukumura Y, Masaoka A, Naito T, Kimura M, Yao T. A case of non-invasive serous adenocarcinoma at unilateral fimbria with spread to the peritoneal/uterine cavity: case report. Diagn Pathol 2009, 4:43. 10.1186/1746-1596-4-43, 3224938, 19961615.
7. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol 1997, 17(1):389-397. 231763, 8972219.
8. Brustmann H. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Gynecol Oncol 2004, 95(1):16-22. 10.1016/j.ygyno.2004.07.040, 15385105.
9. Mano MS, Awada A, Di Leo A, Derbecq V, Paesmans M, Cardoso F, Larsimont D, Piccart M. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol 2004, 92(3):887-895. 10.1016/j.ygyno.2003.12.010, 14984957.
10. Shamaa AA, Zyada MM, Wagner M, Awad SS, Osman MM, Azeem AAA. The significance of Epstein Barr Virus (EBV) & DNA Topoisomerase II alpha (DNA-Topo II alpha) immunoreactivity in normal oral mucosa, Oral Epithelial Dysplasia (OED) and Oral Squamous Cell Carcinoma (OSCC). Diagn Pathol 2008, 3:45. 10.1186/1746-1596-3-45, 2611966, 19021895.
11. Habberstad AH, Gulati S, Torp SH. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, surviving, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an immunohistochemical study. Diagn Pathol 2011, 6:43. 10.1186/1746-1596-6-43, 3127815, 21609421.
12. Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U, Torp SH. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 2011, 4(5):444-453. 3127066, 21738816.
13. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182(3):311-322. 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9, 10653597.
14. Dehari R, Kurman RJ, Logani S, Shih Ie M. The Development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma. A morphologic and molecular genetic analysis. Am J Surg Pathol 2007, 31:1007-1012. 10.1097/PAS.0b013e31802cbbe9, 17592266.
15. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004, 28(4):496-504. 10.1097/00000478-200404000-00009, 15087669.
16. Ayhan A, Kurman RJ, Yemelyanova A, Vang R, Logani S, Seidman JD, Shih Ie M. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol 2009, 33(8):1220-1224. 10.1097/PAS.0b013e3181a24354, 2716424, 19461510.
17. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000, 70(2):209-262.
18. Dogan E, Saygili U, Tuna B, Gol M, Gurel D, Acar B, Koyuncuoglu M. P53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol 2005, 97(1):46-52. 10.1016/j.ygyno.2004.12.053, 15790436.
19. Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih Ie M. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004, 10(19):6432-6436. 10.1158/1078-0432.CCR-04-0893, 15475429.
20. Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, Tronko M, Thomas G. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 2005, 205(5):558-564. 10.1002/path.1736, 15714593.
21. Przybycin CG, Soslow RA. Typing of ovarian carcinomas: an update. Diagn Histopathol 2011, 17(4):165-177.
22. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008, 108(3):510-514. 10.1016/j.ygyno.2007.11.013, 18155273.
23. Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli RL, Shih IM, Bristow RE. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 2007, 17(3):601-606. 10.1111/j.1525-1438.2007.00820.x, 17504374.
24. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009, 114:48-52. 10.1016/j.ygyno.2009.03.001, 19361839.
25. Phol G, Ho CL, Kurman RJ. Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations. Cancer Res 2005, 65(5):1994-2000. 10.1158/0008-5472.CAN-04-3625, 15753399.
26. Diaz-Padilla I, Malpica AL, Minig L, Chiva LM, Gershenson DM, Gonzalez-Martin A. Ovarian low-grade serous carcinoma: A comprehensive update. Gynecol Oncol 2012, 126:279-285. 10.1016/j.ygyno.2012.04.029, 22555104.
27. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2012, S1470-2045(12)70572-7. [Epub ahead of print].
28. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005, 29(8):1034-1041.
29. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003, 91(3):504-512. 10.1016/j.ygyno.2003.08.034, 14675668.
30. Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol 2012, 7:124. 10.1186/1746-1596-7-124, 3523067, 22995373.
31. Mishra SK, Crasta JA. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas. Int J Gynecol Cancer 2010, 20(4):537-541. 10.1111/IGC.0b013e3181d6de3f, 20442586.
32. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008, 61(2):152-163.
33. Parker RL, Clement PB, Chercover DJ, Sornarajah T, Gilks CB. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. Int J Gynecol Pathol 2004, 23(3):265-272. 10.1097/01.pgp.0000130049.19643.f6, 15213603.
34. Smith ER, Smedberg JL, Malgorzata ER, Xu XX. Regulation of Ras-MAPK pathway mitogenic activity by restricting nuclear entry of activated MAPK in endoderm differentiation of embryonic carcinoma and stem cells. J Cell Biol 2004, 164:689-699. 10.1083/jcb.200312028, 2172165, 14981092.
35. Vicent S, Garayoa M, Lopez-Picazo JM, Lozano MD, Toledo G, Thunnissen FBJM, Manzano RG, Montuenga LM. Mitogen-Activated Protein Kinase Phosphatase-1 is Overexpressed in Non-Small Cell Lung Cancer and is an Independent Predictor of Outcome in Patients. Clin Cancer Res 2004, 10:3639-3649. 10.1158/1078-0432.CCR-03-0771, 15173070.
36. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 2010, 177(4):1611-1617. 10.2353/ajpath.2010.100212, 2947258, 20802181.
37. Costa MJ, Hansen CL, Holden JA, Guinee D. Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. Int J Gynecol Pathol 2000, 19(3):248-257. 10.1097/00004347-200007000-00009, 10907174.
38. Brustmann H. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study. Gynecol Oncol 2004, 92(1):268-276. 10.1016/j.ygyno.2003.10.029, 14751170.